120 related articles for article (PubMed ID: 22229850)
21. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal stromal tumors.
von Mehren M; Watson JC
Hematol Oncol Clin North Am; 2005 Jun; 19(3):547-64, vii. PubMed ID: 15939196
[TBL] [Abstract][Full Text] [Related]
23. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
24. Gastrointestinal stromal tumors and the evolution of targeted therapy.
Sanborn RE; Blanke CD
Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
[TBL] [Abstract][Full Text] [Related]
25. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic targets in gastrointestinal stromal tumors].
Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
[TBL] [Abstract][Full Text] [Related]
27. An update on molecular genetics of gastrointestinal stromal tumours.
Tornillo L; Terracciano LM
J Clin Pathol; 2006 Jun; 59(6):557-63. PubMed ID: 16731599
[TBL] [Abstract][Full Text] [Related]
28. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
29. Successes and limitations of targeted cancer therapy in gastrointestinal stromal tumors.
Casali PG
Prog Tumor Res; 2014; 41():51-61. PubMed ID: 24727986
[TBL] [Abstract][Full Text] [Related]
30. [Gastrointestinal stromal tumor molecular diagnostics in relation to the prediction of a therapeutic response to targeted biological therapy].
Augustináková A; Kodet R
Cesk Patol; 2011 Oct; 47(4):148-52. PubMed ID: 22145212
[TBL] [Abstract][Full Text] [Related]
31. Molecular Pathogenesis of Gastrointestinal Stromal Tumor: A Paradigm for Personalized Medicine.
Dermawan JK; Rubin BP
Annu Rev Pathol; 2022 Jan; 17():323-344. PubMed ID: 34736340
[TBL] [Abstract][Full Text] [Related]
32. miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers.
Nannini M; Ravegnini G; Angelini S; Astolfi A; Biasco G; Pantaleo MA
Epigenomics; 2015; 7(6):1033-49. PubMed ID: 26447534
[TBL] [Abstract][Full Text] [Related]
33. [Correlation between mutational types and targeted treatment in gastrointestinal stromal tumors].
Shi EY; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2008 Aug; 37(8):555-8. PubMed ID: 19094470
[No Abstract] [Full Text] [Related]
34. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
McIntire M; Redston M
Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
[TBL] [Abstract][Full Text] [Related]
35. GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer.
Cioffi A; Maki RG
J Clin Oncol; 2015 Jun; 33(16):1849-54. PubMed ID: 25918303
[TBL] [Abstract][Full Text] [Related]
36. Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing.
Hagemann IS; Govindan R; Javidan-Nejad C; Pfeifer JD; Cottrell CE
J Thorac Oncol; 2014 Feb; 9(2):e12-6. PubMed ID: 24419427
[TBL] [Abstract][Full Text] [Related]
37. Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments.
Pogorzelski M; Falkenhorst J; Bauer S
Curr Opin Oncol; 2016 Jul; 28(4):331-7. PubMed ID: 27163723
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy.
Savonarola A; Palmirotta R; Guadagni F; Silvestris F
Pharmacogenomics J; 2012 Aug; 12(4):277-86. PubMed ID: 22760589
[TBL] [Abstract][Full Text] [Related]
39. Role of genetic and molecular profiling in sarcomas.
Norberg SM; Movva S
Curr Treat Options Oncol; 2015 May; 16(5):24. PubMed ID: 25939540
[TBL] [Abstract][Full Text] [Related]
40. Small bowel sarcoma: Tumor biology and advances in therapeutics.
Shenoy S
Surg Oncol; 2015 Sep; 24(3):136-44. PubMed ID: 26278844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
